A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

Following the clinical success achieved with the first generation of adoptive cell therapy (ACT) utilizing in vitro expanded tumor-infiltrating lymphocytes (TILs), the second and third generations of TIL ACT are evolving toward the use of genetically modified TIL. TIL therapy generally involves the...

Full description

Bibliographic Details
Main Authors: Marie-Andrée Forget, René J. Tavera, Cara Haymaker, Renjith Ramachandran, Shuti Malu, Minying Zhang, Seth Wardell, Orenthial J. Fulbright, Chistopher Leroy Toth, Audrey M. Gonzalez, Shawne T. Thorsen, Esteban Flores, Arely Wahl, Weiyi Peng, Rodabe N. Amaria, Patrick Hwu, Chantale Bernatchez
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Immunology
Subjects:
tumor-infiltrating lymphocytes
retroviral-transduction
adoptive cell therapy
genetic modification
Good Manufacturing Practice
clinical-grade
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.00908/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2017.00908/full

Similar Items